Skip to Main Navigation
Skip to Page Content

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Defined Approaches to Identify Potential Skin Sensitizers

Potential skin sensitizers can be identified without animal testing using defined approaches to testing and assessment. A defined approach consists of:

  • Input data generated from identified methods.
  • A data interpretation procedure (e.g., machine-learning model, flowchart, or decision tree through which the data are evaluated).

More about defined approaches to testing and assessment

An adverse outcome pathway can provide a framework for the development of a defined approach. An adverse outcome pathway is a model that identifies the sequence of biochemical events required to produce a toxic effect when an organism is exposed to a substance. In vitro methods can be used to observe or measure the biochemical events and predict whether a substance will produce a toxic effect.

Skin sensitizers are substances with the potential to cause allergic contact dermatitis. Allergic contact dermatitis is an allergic reaction that is often initiated through covalent binding of substances to skin proteins. The events that follow this binding and result in allergic contact dermatitis have been described in an adverse outcome pathway for skin sensitization. NICEATM, working with NTP, ICCVAM, and industry scientists, has created and evaluated defined approaches to identify potential skin sensitizers based on this adverse outcome pathway.

In April 2018, EPA released a draft Science Policy to reduce animal use by using defined approaches to identify potential skin sensitizers. The draft policy is the result of national and international collaboration among ICCVAM, NICEATM, Cosmetics Europe, the European Union Reference Laboratory for Alternatives to Animal Testing, and Health Canada's Pest Management Regulatory Agency.

Defined Approaches Developed by ICCVAM

Defined approaches developed by NICEATM and ICCVAM use non-animal data to predict skin sensitization hazard and potency. These defined approaches combine data from the following sources:

  • Direct peptide reactivity assay (DPRA).
  • KeratinoSens assay.
  • Human cell line activation test (h-CLAT).
  • Read-across predictions generated by the QSAR Toolbox software package.
  • Physical properties (e.g., partition coefficients).

The defined approaches were described in papers published in 2016 and 2017:

  • Strickland et al. 2016 described prediction of murine local lymph node assay outcomes.
  • Strickland et al. 2017 used data from human exposures to predict human skin sensitization hazard.
  • Zang et al. 2017 described prediction of human or animal skin sensitization potency, enabling the classification of skin sensitizers as "weak" or "strong" without animal tests.
To expand the potential applicability of these defined approaches to a broader range of chemical types, ICCVAM agencies nominated over 200 chemicals for additional testing in the DPRA, KeratinoSens, and h-CLAT tests. Chemicals being tested include pesticide ingredients and formulations, industrial chemicals, and personal care product ingredients. NTP is conducting this testing, which began in 2017 and will be completed in 2020.

Collaboration With Cosmetics Europe to Evaluate Defined Approaches

NICEATM and Cosmetics Europe collaborated to evaluate multiple defined approaches for skin sensitization safety assessment that had been submitted to OECD. The collaboration produced two publications:

  • Hoffman et al. 2018 describes a database including data from human, animal, and five non-animal tests for 128 substances. The substances in the database have a variety of chemical structures and use categories. The database is a proposed point of reference for the evaluation and development of new non-animal approaches to skin sensitization safety assessment.
  • Kleinstreuer et al. 2018 describes an analysis of multiple defined approaches for skin sensitization safety assessment of cosmetic ingredients using the database described above. Many of these approaches were found to perform as well or better than animal methods to predict human skin sensitization hazards.

Collaboration With P&G to Develop an Open-Source Integrated Testing Strategy

An integrated testing strategy is a type of defined approach that relies on:

  • Input data generated from identified methods.
  • A data interpretation procedure such as a machine-learning model, flowchart, or decision tree, through which the data are evaluated.
  • A simultaneous assessment of the input data to arrive at either a hazard prediction or a decision that more testing is needed.

NICEATM and other NTP scientists collaborated with scientists at Procter & Gamble (P&G) to develop an integrated testing strategy to identify potential skin sensitizers without conducting animal tests. Using data from non-animal tests and other information (e.g., substance solubility), the strategy produces a numerical probability that a chemical should be placed in one of the following skin sensitization hazard classes:

  • Strong
  • Moderate
  • Weak
  • Nonsensitizer

This probability could potentially be used to determine if a substance requires hazard labeling. P&G and NTP scientists collaborated to develop this integrated testing strategy using free, publicly available software (Pirone et al. 2014).

P&G updated the integrated testing strategy in 2015. The updated strategy (Jaworska et al. 2015) uses only validated non-animal tests, simplifies the bioavailability inputs, and nearly doubles the size of the database used to derive the previous network. The updated P&G integrated strategy is included in a web tool produced by Edelweiss Connect that can be used to predict a substance's skin sensitization potency.

Files for Running the Open-source Integrated Testing Strategy Analysis

Files to run the analysis described in Pirone et al., including a script that uses the R programming language, are available below.

Additional Resources
  • A bioavailability calculator is available from the National Institute for Occupational Safety and Health (NIOSH) website. Please note that Java must be enabled in your web browser in order to run the calculator.
  • The software for running R can be obtained from the R Project website. Refer to the FAQs on the R Project website for system requirements and installation instructions.
  • The OECD QSAR Toolbox can be obtained from the OECD website. Installation instructions and user documentation are available on this page.

NICEATM Murine Local Lymph Node Assay (LLNA) Database

On behalf of ICCVAM, NICEATM conducted analyses to evaluate the usefulness of the LLNA to identify potential skin sensitizers. Data from these analyses are available as a reference for developing and evaluating alternatives to animal use for identification of potential skin sensitizers.

  • NICEATM LLNA database
  • Notes for Database Users
    • The Excel spreadsheet contains three pages:
      1. Data
      2. References
      3. Abbreviations
    • The database includes data published through 2010.
    • These data have been extracted from published and unpublished data sources with permission. Users of this database should consult the original data source for questions regarding data quality and/or authenticity.